firm or refute these concerns. We chose to select for WT1 vaccine treatment only those patients with progressing MDS with excess of blasts, because prevention or delay of overt leukemia could outweigh the disadvantage of inducing cytopenia.
No takes yet. Share an insight, caveat, or question.
Gluckman et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: